|Videos|July 6, 2021

Dr. Casey Seideman on why women should consider specializing in urology

Author(s)Urology Times staff

Casey Seideman, MD, shares her thoughts on why women who want to go into a surgical subspecialty should consider urology. Seideman is assistant professor of Urology, School of Medicine, Oregon Health & Science University.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom

ByJonathan Rubenstein, MD,Mark Painter

August 21st 2026

Pearls & Perspectives: Patient Expectations, Physician Autonomy, and Life Beyond Surgery, With Andrew T. Cohen, MD, FACS

ByAmy M. Pearlman, MD,Andrew T. Cohen, MD, FACS

August 12th 2026

Jessica Yih, MD, highlights data on testosterone therapy in women

ByJessica M. Yih, MD

August 11th 2026

Pearls & Perspectives: Wearable Technology and the Future of Sexual Health, With Elliot Justin, MD

ByAmy M. Pearlman, MD,Larry Lipshultz, MD,Elliot Justin, MD, FACEP

August 5th 2026

From hype to practice: Urologists assess AI's real impact

ByHannah Clarke

July 30th 2026

Latest CME

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy

FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent

Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery